$49.91
1.86%
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US4158581094
Symbol
HROW

Harrow Health, Inc. Stock price

$49.91
+9.74 24.25% 1M
+19.34 63.26% 6M
+0.91 1.86% YTD
+13.35 36.52% 1Y
+35.15 238.14% 3Y
+42.56 579.05% 5Y
+43.11 633.97% 10Y
+41.26 477.09% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.91 1.86%
ISIN
US4158581094
Symbol
HROW
Industry

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$2.0b
Net debt
$168.6m
Cash
$74.3m
Shares outstanding
37.0m
Valuation (TTM | estimate)
P/E
negative | 475.7
P/S
7.4 | 6.7
EV/Sales
8.1 | 7.3
EV/FCF
negative
P/B
39.3
Financial Health
Equity Ratio
17.9%
Return on Equity
-25.1%
ROCE
9.5%
ROIC
-
Debt/Equity
5.2
Financials (TTM | estimate)
Revenue
$250.0m | $277.4m
EBITDA
$46.9m | $72.0m
EBIT
$28.2m | $37.4m
Net Income
$-5.0m | $3.9m
Free Cash Flow
$-20.8m
Growth (TTM | estimate)
Revenue
47.8% | 39.0%
EBITDA
1,277.9% | 217.2%
EBIT
428.6% | 311.7%
Net Income
85.1% | 122.3%
Free Cash Flow
-779.7%
Margin (TTM | estimate)
Gross
74.6%
EBITDA
18.7% | 26.0%
EBIT
11.3%
Net
-2.0% | 1.4%
Free Cash Flow
-8.3%
More
EPS
$-0.1
FCF per Share
$-0.6
Short interest
19.1%
Employees
382
Rev per Employee
$520.0k
Show more

Is Harrow Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Harrow Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Harrow Health, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Harrow Health, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Harrow Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
250 250
48% 48%
100%
- Direct Costs 63 63
37% 37%
25%
186 186
52% 52%
75%
- Selling and Administrative Expenses 145 145
20% 20%
58%
- Research and Development Expense 14 14
29% 29%
6%
47 47
1,278% 1,278%
19%
- Depreciation and Amortization 19 19
56% 56%
7%
EBIT (Operating Income) EBIT 28 28
429% 429%
11%
Net Profit -4.99 -4.99
85% 85%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Harrow Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harrow Health, Inc. Stock News

Neutral
Investors Business Daily
25 days ago
Biotech stock Harrow is in a cup base with a buy point of 50.72 after third-quarter results.
Neutral
Seeking Alpha
27 days ago
The Undercovered Dozen spotlights 12 lesser-known stocks and funds with compelling investment theses and recent developments. This week's edition covers articles published between Nov. 28 and Dec. 4, offering fresh investment ideas. The series aims to inspire discussion and help investors discover overlooked opportunities in the market.
Positive
The Motley Fool
about one month ago
Philadelphia-based Penn Capital Management added 325,478 shares of Harrow for an estimated $15.7 million in the third quarter. The move created a new position for Penn, which did not report holding any shares of Harrow in the previous quarter.
More Harrow Health, Inc. News

Company Profile

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Head office United States
CEO Mark Baum
Employees 382
Founded 2006
Website www.harrow.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today